Overview
Status
Active
Registry date
2003-01-15
Share capital
2,808,603.00 PLN
Registered address
12, 64-030 Parsko, Poland
Electronic delivery address
AE:PL-90353-20345-ISWUC-08
Financials
Revenue history (in k)
Filing timeliness
5 of 6 financial statements were filed late (the longest delay 96 days for 2022). 2 of 6 audited by a statutory auditor.
- 202517/08/2026
- 202415/09/2025
- 202301/08/2024
- 202219/10/2023
- 202114/10/2022
- 202008/07/2021
Filed on timeDelayFiling deadline
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Division · Manufacture of basic pharmaceutical products and pharmaceutical preparations181 / 231
Top 78%
Results vs industry
Revenue
This companyUSD 70.07kMedianUSD 919.05kAverageUSD 25.83m
Net profit
This companyUSD -24.14kMedianUSD 14.92kAverageUSD 2.77m
Operating costs
This companyUSD 94.21kMedianUSD 873.06kAverageUSD 21.43m
Assets
This companyUSD 95.74kMedianUSD 897.46kAverageUSD 31.52m
Industry
Trademarks
Nika Health Products currently holds no active trademarks with the Polish Patent Office. 1 mark has expired or was not registered. The first mark was filed in 1993.
| Mark | Protected until | |
|---|---|---|
| LYDIUM KLP(word) | – |
Authorized Representatives
Czesław Janicki – Attorney-in-fact (sole)
Grzegorz Karol Nowak – President
Manner of representation
Independent representation.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Ewa Maria Janicka Thomasage 72 | 2,289 | $379,335.90 | 50% |
Grzegorz Karol Nowakage 65 | 2,289 | $379,335.90 | 50% |
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2004-07-01.
96 1020 4160 0000 2002 0223 0472
Debt
No entries in the National Debtors Register (KRZ).
MSiG notices
| Publication date | Event | |
|---|---|---|
| Oct 7, 2010 | Call to creditors |
Public aid
No public aid cases recorded in the last 10 years.
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Delpharm PoznańS.A. | $110,900,246.81 | delpharm.com | ||
| Phytopharm KlękaS.A. | $46,154,888.31 | phytopharm.pl | ||
| Poznańskie Zakłady Zielarskie HerbapolS.A. | $31,668,225.77 | herbapol.poznan.pl | ||
| Curtis Health CapsS.A. | $30,831,117.38 | chc.com.pl | ||
| Przedsiębiorstwo Farmaceutyczne Farmapolsp. z o.o. | $21,462,728.43 | farmapol.pl | ||
| Przedsiębiorstwo Produkcyjno-Handlowe EwaS.A. | $14,322,437.53 | ewa-sa.pl | ||
| LideoS.A. | $95,067.91 | lideo.tech | ||
| Munar PharmaS.A. | $85,649.72 | munar.pl | ||
| Ampliconsp. z o.o. | $48,330.99 | amplicon.pl | ||
| Xenira Pharmaceuticalssp. z o.o. | $26,670.82 | xenirapharma.com |
Change history
| Date | Event | |
|---|---|---|
| 2012-02-28 | Address change (Fabryczna 11, 55-080, Kąty Wrocławskie → 12, 64-030, Parsko) | |
| 2010-02-16 | Switch to PKD 2007 (9 PKD 1997 codes → 6 PKD 2007 codes) | |
| 2004-12-09 | Share capital reduction (3,360,753.00 PLN → 2,808,603.00 PLN) | |
| 2004-06-01 | Address change (Jeżycka 43/2, 60-864, Poznań → Fabryczna 11, 55-080, Kąty Wrocławskie) | |
| 2004-03-01 | Share capital increase (2,331,300.00 PLN → 3,360,753.00 PLN) |
FAQ
The main business activity of Nika Health Products focuses on manufacture of pharmaceutical preparations.
The company was registered in the Polish National Court Register (KRS) on January 15, 2003.
The headquarters is located at: 12, 64-030 Parsko.
The share capital of the company is PLN 2,808,603 (approx. $758,672).
The latest available financial statement covers the period from January 1, 2025 to December 31, 2025.
In 2025, the company generated total revenue of USD 70,065, representing an increase of 6.5% compared to 2024.
No, in 2025 the company was not profitable, reporting a net loss of USD 24,144. For comparison, in 2024 the loss was USD 45,373, meaning the company reduced its loss by 46.9%.
The largest operating cost category falls under other operating costs. This category amounted to USD 61,881 in 2025, representing 66% of all operating expenses.
Last updated: 2026-09-01